Anemia Clinical Trial
Official title:
A Multicenter, Phase Ib/II Trial of the Safety and Efficacy of Umbilical Cord Derived Mesenchymal Stem Cells in Treatment-induced Myelosuppression in Patients With Hematologic Malignancies (USMYE Trial)
The purpose of the study is to explore the safety and efficacy of umbilical cord derived mesenchymal stem cells in treatment-induced myelosuppression in patients with hematologic malignancies.
Status | Not yet recruiting |
Enrollment | 181 |
Est. completion date | January 31, 2025 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Aged between 18 and 75 years old; 2. Either type of primary hematologic malignancies listed below: 1. Acute myeloid leukemia (AML, AML subtype M3 excluded) or acute lymphoblastic leukemia (ALL) diagosed according to the 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, either treatment naive participants who are going to receive first induction therapy, or participants who failed first induction therapy and are going to receive re-inducton therapy; 2. AML or ALL participants who achieved remission and are going to receive consolidation therapy; 3. Relapsed/refractory AML or ALL participants who are going to receive first re-induction therapy; 4. Phase II trial will also include: participants with primary hematological maligancies who are going to receive autologous hematopoietic stem cell transplantation (allo-HSCT) whereas are poor mobilizers (CD34+cell count in peripheral blood was below 11-19/µL before collection, or the amount of CD34+ cells transfused was below 2×10^6/kg in allo-HSCT), and the participants' peripheral superficial veins have smooth blood flow which can meet the demand for intravenous drip; 3. The participant or his/her legal guardian is adequately informed of the nature and risks of the study, voluntarily participates in the study with signed informed consent; 4. Male or female; 5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2 (by the day anti-cancer therapy is initiated) 6. Estimated survival of at least 3 months; 7. Adequate major organ function: 1. Respiratory function: indoor oxygen saturation of at least 95%; 2. Cardiac function: ejection fraction of left ventricular of at least 45%; 3. Hepatic function: alanine aminotransferase/aspartate aminotransferase of at most 2.5 times/upper limit of normal value and serum total bilirubin of at most 1.5 times/upper limit of normal value; 4. Renal function: Serum creatinine of at most 1.5 times/upper limit of normal value; 8. Participants who do not receive any type of anti-cancer therapy within 2 weeks before enrollment (radiation therapy, chemotherapy and/or immune therapy, et al.), and treatment-associated toxicities induced by previous therapy has recovered to Grade 1 or below (except for low grade toxities such as alopecia). Exclusion Criteria: 1. Overt central nervous system manifestations of hematologic malignancies at diagnosis; 2. Secondary hematological maligancies; 3. Body mass index (BMI) of more than 30 kg/m^2; 4. Myelosuppression induced by conditions other than anti-cancer therapy; 5. Previous radiation therapy performed on sternum or pelvis; 6. Specifically diagnosed and uncontrolled infection at enrollment (Uncontrolled is defined as exhibiting ongoing signs and symptoms of infection without improvement despite anti-infective agents) ; 7. Uncontrolled active bleeding at enrollment; 8. Severe underlying comorbidities affecting survival, including cachexia, severe malnutrition, etc; 9. Estimated survival of at most 48 hours; 10. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection; 11. History of or current human immunodeficiency virus (HIV) infection; 12. Continuous usage of immunosuppressants or received organ transplantation in the last 6 months; 13. Participation in clinical trials of other drugs within 6 weeks before enrollment; 14. Previous participation in clinical stem cell research; 15. Receiving any agent concurrently with UC-MSCs infusion which inhibits cell division (hydroxyurea, low-dose cytarabine or methotrexate, etc) ; 16. Severe allergic constitution, or known or suspected allergy to the study drug and its components; 17. Known contraindication to receiving hematopoietic growth factors, transfusion of blood components, anti-infective agents; 18. Female participants who are pregnant or breast feeding; 19. Participants with fertility plan; Note: For female participants, they should be surgical sterilized or post-menopausal, or agree to utilize a medically recognised method of contraception (such as intrauterine device, condom) during treatment period of the study and within 6 months after the end of treatment period of the study; For male participants, they should be surgical sterilized or agree to utilize a medically recognised method of contraception (such as intrauterine device, condom) during treatment period of the study and within 6 months after the end of treatment period of the study; 20. Participants suffering from mental illness; 21. Presence of drug abuse/addiction; 22. History of other malignancies other than hematological malignancies within 3 years; 23. Participants without signed informed consent; 24. Participants with poor compliance and are unable to complete the whole course of the study; 25. Participants with circumstances that, in the opinion of the investigator, may increase the risk of the participants or interfere with conduct of the clinical trial and the judgment of results (excessive tension, sensitivity or cognitive impairment, etc) ; 26. Participants with other circumstances that are ineligible for enrollment in this study, in the opinion of the investigator. |
Country | Name | City | State |
---|---|---|---|
China | Wuhan Central Hospital | Wuhan | Hubei |
China | Wuhan Tongji Hospital | Wuhan | Hubei |
China | Wuhan Union Hospital | Wuhan | Hubei |
Lead Sponsor | Collaborator |
---|---|
Wuhan Union Hospital, China | Wuhan Central Hospital, Wuhan TongJi Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Dose-limiting toxicities(DLT) | During the DLT observation period, the subject has an adverse event that is reasonably related to UC-MSCs infusion (possibly, likely or definitely related). | 4 days after the last UC-MSCs dose, up to 12 days | |
Primary | Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) | To investigate the safety characteristics, percentages will be calculated and grade will be evaluated. | From the day that the last UC-MSCs dose is used to up to 21 days | |
Primary | Maximum tolerated dose (MTD) | During the dose-escalation phase, the highest dose of dose-limiting toxicity for subjects less than or equal to 1/3 in the dose group of at least 6 evaluble subjects of the study drug after the last UC-MSCs dose. | From the day that the last UC-MSCs dose is used to up to 4 days | |
Secondary | Time to absolute neutrophil count recovery | To investigate the efficacy characteristics, time will be measured in days. | From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days | |
Secondary | Incidence of febrile neutropenia | To investigate the efficacy characteristics, percentages will be calculated. | From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days | |
Secondary | Duration of febrile neutropenia | To investigate the efficacy characteristics, the duration will be measured in days. | From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days | |
Secondary | Incidence of severe thrombocytopenia | To investigate the efficacy characteristics, percentages will be calculated. | From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days | |
Secondary | Time to severe thrombocytopenia recovery | To investigate the efficacy characteristics, time will be measured in days. | From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days | |
Secondary | Incidence of severe anemia | To investigate the efficacy characteristics, percentages will be calculated. | From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days | |
Secondary | Time to severe anemia recovery | To investigate the efficacy characteristics, time will be measured in days. | From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days | |
Secondary | Incidence of infetion | To investigate the efficacy characteristics, percentages will be calculated. | From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days | |
Secondary | Duration of infetion | To investigate the efficacy characteristics, the duration will be measured in days. | From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days | |
Secondary | Incidence of bleeding | To investigate the efficacy characteristics, percentages will be calculated. | From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days | |
Secondary | Duration of bleeding | To investigate the efficacy characteristics, the duration will be measured in days. | From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days | |
Secondary | Application rate of blood transfusion | To investigate the efficacy characteristics, percentages will be calculated. | From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days | |
Secondary | Application rate of anti-infective agents | To investigate the efficacy characteristics, percentages will be calculated. | From the start of anti-cancer therapy or completion of hematopoietic stem cell transplantation to up to 42 days | |
Secondary | Time to achievement of complete remission | To investigate the efficacy characteristics, time will be measured in days. | From enrollment to up to 28 days | |
Secondary | Duration of complete remission | To investigate the safety characteristics, the duration will be measured in days or months. | From enrollment to maximun up to 2 years | |
Secondary | Event free survival | From enrollment to the day of any event. | From enrollment to maximun up to 2 years | |
Secondary | Overall survival | From enrollment to the day of death caused by any reason. | From enrollment to maximun up to 2 years | |
Secondary | Incidence of infusion reactions in 2 years | To investigate the safety characteristics, percentages will be calculated. | 2 years since the last UC-MSCs infusion | |
Secondary | Incidence of secondary tumor in 2 years | To investigate the safety characteristics, percentages will be calculated. | 2 years since the last UC-MSCs infusion | |
Secondary | Cumulative incidence of relapse of primary disease in 2 years | To investigate the safety characteristics, percentages will be calculated. | 2 years since the last UC-MSCs infusion |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 | |
Terminated |
NCT01535781 -
Study of the Effect of Tranexamic Acid Administered to Patients With Hip Fractures. Can Blood Loss be Reduced?
|
N/A |